1 / 18

Ellingson BM et al ., Neuro Oncol. 2012 14(4):333-43.

Ellingson BM et al ., Neuro Oncol. 2012 14(4):333-43. Ellingson BM et al ., Neuro Oncol. 2012 14(4):333-43. Ellingson BM et al., Neuro Oncol. 2011 13(10):1151-61. Instead of quantifying the absolute difference in ADC, CIMPLE

glenna-hunt
Télécharger la présentation

Ellingson BM et al ., Neuro Oncol. 2012 14(4):333-43.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ellingson BM et al., Neuro Oncol. 2012 14(4):333-43.

  2. Ellingson BM et al., Neuro Oncol. 2012 14(4):333-43. Ellingson BM et al., Neuro Oncol. 2011 13(10):1151-61

  3. Instead of quantifying the absolute difference in ADC, CIMPLE • maps examines the rate of change and spatial changes in ADC • PROLIFERATION MAPPING uses the CIMPLE map equation, • but assumes no invasion (simplified version of CIMPLE map…need only two time points). • Example: If ADC in one region has decreased from 1.6 to 1.0 um2/ms • over the course of 1 year and another region has a decrease in ADC from 1.6 to 1.0 um2/ms over the course of the last month, fDMs would say these are equally “hypercellular”. CIMPLE maps (or proliferation maps) would say that these two regions have different rates of change in ADC and therefore different proliferation rates. fDMs CIMPLE/ Proliferation Maps

More Related